MARIA FERNANDA WAH AGUILAR

Accomplished Physician with extensive experience caring for patients in various capacities. Highly organized and detail-oriented professional with strong work ethic and dedication to achieving goals. Offers compassionate and dedication to quality patient care.

• GCP for Clinical Trials with Investigational Drugs and Biologic's (ICH Focus)
• OSHA Bloodborne Pathogens
• HIPPA Awareness for Healthcare Providers, HIPAA Training.
• Medidata Rave EDC
• Certified in Aesthetic Medicine and Antiaging by Mexican Congress of Aesthetic.
• Certified in Phlebology and Lymphology by Mexican Institute of Phlebology.
• Certified in Derma Threads by Smart Medical Technology.
• Certified in Botox, Derma Fillers, Platelet Rich Plasma by National Association of Aesthetic Medicine.
• Congress in Phlebology by Mexican Institute of Phlebology.

• PUBLISHED CASE REPORT IN ENDORIUM JOURNALS
• Autoimmune hemolytic anemia presenting concurrently with thrombotic thrombocytopenia purpura

• Microsoft Word
• Microsoft PPT
• Microsoft Excel
• OncoEMR (OncoTrials)
• Tempus
• Sepstream
• Labcorp link
• Medidata rave
• eCW

Phase I

• ART-123.PN101, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients

Phase II

• SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
• A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung, D933LC00001
• A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer, SGN35-033, A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
• GSK, Efficacy Comparison of Cobolimab + Dostorlimab + Docetaxel to Docetaxel alone in participants with advanced Non-Small Cell Lung Cancer who have progressed on prior anti-PD-(L)1 therapy and Chemotherapy
• Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy.

Phase III

• FRNM-008, The Vallania Study: A case control study for the development of Multiomics blood tests for cancer screenings.

Glacial Rx

R2 Technologies Glacial Rx Clinical Study for patients with post surgical scar pain and “pocket pain”. In neuromodulation at the site of device implant. 

R2 Technologies Glacial Rx Clinical Study for patients with history of Trigeminal Neuralgia who have not received pain relief.